

INVITATION

FRIDAY
23
SEPT

08:30 – 09:30
CET

Role of ECP Immunomodulation in current treatment strategies for CTCL

EORTC – CLTG 2022 – Hospital 12 de
Octubre – Auditorium, Madrid

This information is intended for healthcare professionals in Europe

- Moderator** Prof Robert Knobler, Medical University of Vienna, Austria
- 08:30 – 08:55 **ECP in the current International Guidelines & Clinical update**
Prof Julia Scarisbrick, University Hospital Birmingham, United Kingdom
- 08:55 – 09:20 **Role of ECP in the management of CTCL – Spanish experience**
Prof Pablo Ortiz, Hospital Universitario 12 de Octubre, Madrid, Spain
- 09:20 – 09:30 **Q&A**

ECP: Extracorporeal Photopheresis, CTCL: Cutaneous T-cell Lymphoma

All speakers are subject to contract.

**This is a commercial programme run by Therakos (UK) Ltd,
a Mallinckrodt Company.**

Follow the
Therakos Institute



[Privacy policy](#)

For more information on THERAKOS ECP Immunomodulation™ please visit www.therakos.eu
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt
company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

© 2022 Mallinckrodt. Item code: EU-2200168. Date of preparation: June 2022.

*Although we have determined that we have a legitimate interest in using your data for marketing
and sales purposes as per the terms of the current data protection legislation, you can opt-out
by replying to this mail indicating “unsubscribe” in the email body. Our Privacy Notice provides
additional information.*